Alkermes (ALKS) Income from Continuing Operations (2010 - 2026)
Alkermes (ALKS) posted quarterly Income from Continuing Operations of 524000.0 for Q2 2026, down 99.4% year-over-year from 87098000.0 in Q2 2025, and up 100.79% quarter-over-quarter from 66526000.0 in Q1 2026.
Alkermes (ALKS) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Income from Continuing Operations for 17 consecutive years, with 524000.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations fell 99.4% year-over-year to 524000.0; the TTM figure through Jun 2026 stood at 66134000.0 (down 81.0% YoY), while the FY2025 annual figure was 241664000.0, down 35.06% from the prior year.
- Income from Continuing Operations climbed to 524000.0 in Q2 2026 per ALKS's latest filing, from 66526000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 279101000.0 in Q2 2023 and bottomed at 66526000.0 in Q1 2026.
- Historically, Income from Continuing Operations has averaged 56923000.0 across 5 years, with a median of 66068000.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations sank 1374.79% — and 2023, when it jumped 1026.14%.
- Alkermes' Income from Continuing Operations stood at 87716000.0 in 2022, then soared by 83.04% to 160554000.0 in 2023, then retreated by 9.2% to 145777000.0 in 2024, then plunged by 66.12% to 49391000.0 in 2025, then tumbled by 98.94% to 524000.0 in 2026.
- Business Quant data shows ALKS's Income from Continuing Operations at 524000.0 in Q2 2026, 66526000.0 in Q1 2026, and 49391000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.42 Bn | 39.76 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.98 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.29 Bn | 19.63 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.78 Bn | 17.89 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.66 Bn | 15.27 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 11.91 Bn | 11.38 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Alkermes | 8.20 Bn | 7.55 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 524,000.00 |
| Mar 31, 2026 | -66.53 Mn |
| Dec 31, 2025 | 49.39 Mn |
| Sep 30, 2025 | 82.75 Mn |
| Jun 30, 2025 | 87.10 Mn |
| Mar 31, 2025 | 22.46 Mn |
| Dec 31, 2024 | 145.78 Mn |
| Sep 30, 2024 | 92.80 Mn |
| Jun 30, 2024 | 94.62 Mn |
| Mar 31, 2024 | 38.91 Mn |
| Dec 31, 2023 | 160.55 Mn |
| Sep 30, 2023 | 91.51 Mn |
| Jun 30, 2023 | 279.10 Mn |
| Mar 31, 2023 | -12.05 Mn |
| Dec 31, 2022 | 87.72 Mn |
| Sep 30, 2022 | -63.97 Mn |
| Jun 30, 2022 | -30.14 Mn |
| Mar 31, 2022 | -35.90 Mn |
| Dec 31, 2021 | 125.44 Mn |
| Sep 30, 2021 | -28.99 Mn |